Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2024

The irritable bowel syndrome (ibs) treatment market size has grown rapidly in recent years. It will grow from $2.5 billion in 2023 to $2.77 billion in 2024 at a compound annual growth rate (CAGR) of 10.8%. The growth observed in the historical period can be attributed to several factors, including the increasing prevalence of irritable bowel syndrome (IBS), a rise in patient awareness, the influence of stress and lifestyle factors, the presence of patient advocacy and support groups, and the impact of healthcare reimbursement policies.

The irritable bowel syndrome (ibs) treatment market size is expected to see rapid growth in the next few years. It will grow to $4.29 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The anticipated growth in the forecast period can be attributed to factors such as the adoption of patient-centric healthcare models, the exploration of microbial therapies, the integration of blockchain in healthcare, a focus on patient-reported outcomes (PROs), the implementation of regulatory fast-track programs, and advancements in health data interoperability. Prominent trends expected in the forecast period encompass the integration of digital health solutions, advancements in diagnostic technologies, increased investments in research and development, collaborations and partnerships within the healthcare industry, and the emergence of non-pharmacological therapies.

The anticipated growth of the irritable bowel syndrome (IBS) treatment market is driven by the increasing prevalence of irritable bowel syndrome (IBS). IBS is a chronic gastrointestinal disorder affecting the large intestine, and its rising prevalence is attributed to poor lifestyles, unhealthy eating habits, exposure to pollution, and heightened stress levels. Treatment for IBS aims to alleviate symptoms, reduce their severity and frequency, and enhance individuals' ability to manage their conditions effectively. According to the International Foundation for Gastrointestinal Disorders (IFFGD), approximately 5–10% of the global population is expected to have IBS in 2023, with between 25 and 45 million people in the United States affected by the condition. Consequently, the growing prevalence of IBS is a key factor driving the expansion of the IBS treatment market.

The growth of the IBS treatment market is expected to be propelled by the aging population. The aging population refers to a demographic trend characterized by an increasing proportion of elderly individuals within a society. Individuals in this demographic group utilize IBS treatment to manage gastrointestinal symptoms associated with aging, addressing age-related changes in digestive health and promoting a better quality of life by alleviating discomfort and supporting overall well-being. As reported in October 2022 by the World Health Organization (WHO), the global population of individuals aged 60 years and older is rapidly growing and is expected to double by 2050, reaching 2.1 billion. Hence, the aging population is a significant driver for the growth of the IBS treatment market.

A prominent trend in the irritable bowel syndrome (IBS) market is the focus on product innovations by major players. Leading companies in the IBS market are actively engaged in developing new and advanced products to reinforce their market positions. For instance, in April 2022, Ardelyx, a U.S.-based biotechnology company, introduced IBSRELA, a first-in-class treatment for IBS-C in adults. IBSRELA, the first and only NHE3 inhibitor available for treating adult irritable bowel syndrome with constipation (IBS-C), offers a novel mechanism therapy for IBS-C and represents a significant new treatment option for constipation, bloating, and stomach pain associated with this debilitating disorder.

Major companies in the irritable bowel syndrome (IBS) market are adopting a strategic partnership approach to address conditions such as Crohn's disease and ulcerative colitis. Strategic partnerships involve collaboration between companies to leverage each other's strengths and resources for mutual benefits. In October 2023, Sanofi S.A., a France-based pharmaceutical industry company, formed a partnership with Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, aiming to provide treatment for inflammatory bowel disease.

In October 2023, Roche, a Switzerland-based healthcare company, acquired Telavant Holdings for an undisclosed amount. Through this acquisition, Roche gains the rights to develop, manufacture, and market a novel treatment for Irritable Bowel Syndrome (IBS) in the United States and Japan. Telavant Holdings, a U.S.-based biotechnology company, specializes in developing and commercializing innovative therapies for inflammatory and fibrotic diseases.

Major companies operating in the irritable bowel syndrome (ibs) treatment market report are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc. , Astellas Pharma Inc., Biogen Inc., Bausch Health Companies Inc., UCB SA, SK Biopharmaceuticals Co. Ltd., Celltrion Healthcare Co. Ltd., Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Protalix Biotherapeutics, Cosmo Technologies Ltd., Renexxion Ireland Ltd., 4D Pharma PLC, Biora Therapeutics Inc.

North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (ibs) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the irritable bowel syndrome (ibs) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of drugs used in irritable bowel syndrome (IBS) treatment include lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others. Lubiprostone, for instance, is a medication employed in treating IBS. It functions as a selective chloride channel activator, facilitating increased fluid secretion in the intestines. The drug is indicated for IBS with constipation, IBS with diarrhea, and IBS with alternating constipation and diarrhea. These medications are distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies, catering to diverse end-users such as hospitals, clinics, and home care settings.

The irritable bowel syndrome (IBS) treatment market research report is one of a series of new reports that provides irritable bowel syndrome (IBS) treatment market statistics, including irritable bowel syndrome (IBS) treatment industry global market size, regional shares, competitors with an irritable bowel syndrome (IBS) treatment market share, detailed irritable bowel syndrome (IBS) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the irritable bowel syndrome (IBS) treatment industry. This irritable bowel syndrome (IBS) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The irritable bowel syndrome (IBS) treatment market includes revenues earned by entities by providing services such as consultation, cognitive-behavioral therapy (CBT), hypnotherapy, psychological therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The irritable bowel syndrome (IBS) market also includes sales of antispasmodics, fiber supplements, laxatives, probiotics, and certain medications targeting gut function. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.